Automated Scar Segmentation from CMR-LGE Images Using a Deep Learning Approach

Aim. The presence of myocardial scar is a strong predictor of ventricular remodeling, cardiac dysfunction and mortality. Our aim was to assess quantitatively the presence of scar tissue from cardiac-magnetic-resonance (CMR) with late-Gadolinium-enhancement (LGE) images using a deep-learning (DL) approach. Methods. Scar segmentation was performed automatically with a DL approach based on ENet, a deep fully-convolutional neural network (FCNN). We investigated three different ENet configurations. The first configuration (C1) exploited ENet to retrieve directly scar segmentation from the CMR-LGE images. The second (C2) and third (C3) configurations performed scar segmentation in the myocardial region, which was previously obtained in a manual or automatic way with a state-of-the-art DL method, respectively. Results. When tested on 250 CMR-LGE images from 30 patients, the best-performing configuration (C2) achieved 97% median accuracy (inter-quartile (IQR) range = 4%) and 71% median Dice similarity coefficient (IQR = 32%). Conclusions. DL approaches using ENet are promising in automatically segmenting scars in CMR-LGE images, achieving higher performance when limiting the search area to the manually-defined myocardial region

Profile, Healthcare Resource Consumption and Related Costs in ANCA-Associated Vasculitis Patients: A Real-World Analysis in Italy

Introduction: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) are rare autoimmune diseases triggering inflammation of small vessels. This real-world analysis was focused on the most common AAV forms, granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), to describe patients’ demographic and clinical characteristics, therapeutic management, disease progression, and the related economic burden. Methods: A retrospective analysis was conducted on administrative databases of a representative sample of Italian healthcare entities, covering approximately 12 million residents. Between January 2010 and December 2020, adult GPA patients were identified by payment waiver code or hospitalization discharge diagnosis, and MPA patients by payment waiver code with or without hospitalization discharge diagnosis. Clinical outcomes were evaluated through AAV-related hospitalizations, renal failure onset, and mortality. Economic analysis included healthcare resource utilization deriving from drugs, hospitalizations, and outpatient specialist services. The related mean direct costs year/patient were also calculated in patients stratified by presence/absence of glucocorticoid therapy and type of inclusion criterion (hospitalization/payment waiver code). Results: Overall, 859 AAV patients were divided into GPA (n = 713; 83%) and MPA (n = 146; 17%) cohorts. Outcome indicators highlighted a clinically worse phenotype associated with GPA compared to MPA. Cost analysis during follow-up showed tendentially increased expenditures in glucocorticoid-treated patients versus untreated (overall AAV: €8728 vs. €7911; GPA: €9292 vs. €9143; MPA: €5967 vs. €2390), mainly driven by drugs (AAV: €2404 vs. €874; GPA: €2510 vs. €878; MPA: €1881 vs. €854) and hospitalizations. Conclusion: Among AAV forms, GPA resulted in a worse clinical picture, higher mortality, and increased costs. This is the first real-world pharmaco-economic analysis on AAV patients stratified by glucocorticoid use on disease management expenditures. In both GPA and MPA patients, glucocorticoid treatment resulted in higher healthcare costs, mostly attributable to medications, and then hospitalizations, confirming the clinical complexity and economic burden for management of patients with autoimmune diseases under chronic immunosuppression

‘It’s about time’. Dissemination and evaluation of a global health systems strengthening roadmap for musculoskeletal health – insights and future directions

Actions towards the health-related Sustainable Development Goal 3.4 typically focus on non-communicable diseases (NCDs) associated with premature mortality, with less emphasis on NCDs associated with disability, such as musculoskeletal conditions—the leading contributor to the global burden of disability. Can systems strengthening priorities for an underprioritised NCD be codesigned, disseminated and evaluated? A ‘roadmap’ for strengthening global health systems for improved musculoskeletal health was launched in 2021. In this practice paper, we outline dissemination efforts for this Roadmap and insights on evaluating its reach, user experience and early adoption. A global network of 22 dissemination partners was established to drive dissemination efforts, focussing on Africa, Asia and Latin America, each supported with a suite of dissemination assets. Within a 6-month evaluation window, 52 Twitter posts were distributed, 2195 visitors from 109 countries accessed the online multilingual Roadmap and 138 downloads of the Roadmap per month were recorded. Among 254 end users who answered a user-experience survey, respondents ‘agreed’ or ‘strongly agreed’ the Roadmap was valuable (88.3%), credible (91.2%), useful (90.1%) and usable (85.4%). Most (77.8%) agreed or strongly agreed they would adopt the Roadmap in some way. Collection of real-world adoption case studies allowed unique insights into adoption practices in different contexts, settings and health system levels. Diversity in adoption examples suggests that the Roadmap has value and adoption potential at multiple touchpoints within health systems globally. With resourcing, harnessing an engaged global community and establishing a global network of partners, a systems strengthening tool can be cocreated, disseminated and formatively evaluated

Analisi degli outcome e del consumo di risorse sanitarie in pazienti con vasculite ANCA-associata in un contesto di pratica clinica in Italia [Analysis of outcomes and healthcare resource consumption in patients with ANCA-associated vasculitis in a setting of clinical practice in Italy]

Introduction. Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are the two most frequent forms of ANCA-associated vasculitis (AAV). The present analysis evaluated the demographic and clinical characteristics of affected patients, their therapeutic management with particular reference to glucocorticoids, outcomes, use of healthcare resources and related costs, in real Italian clinical practice. Materials and methods. A retrospective study was conducted on the administrative databases of Italian healthcare institutions, covering about 9 million health-assisted residents. From 2010 to 2020, adult patients with an exemption code for GPA and/or hospital discharge diagnosis for GPA or an exemption code for MPA with/without a discharge diagnosis for MPA were included. In the pre-inclusion period demographic and clinical data were collected (Charlson Comorbidity-Index-CCI), in the follow-up (1 year) glucocorticoid prescriptions and clinical outcomes (hospitalisations, onset of end-stage renal disease) were recorded. Annual consumption of healthcare resources (drugs, specialist outpatient services, hospitalisations), and related costs to the National Health Service (NHS) were estimated. Results. Of 738 AAV patients, 610 (82.7%) had GPA and 128 (17.3%) MPA. The gender distribution was comparable (except slight female prevalence in the MPA group), the mean age 57 years, regardless of disease form, and the comorbidity profile was worse in the GPA group (CCI=1.3) than in the MPA group (CCI=1.0). Glucocorticoid treatment was predictive of a 2.5-fold increased risk of hospitalisation/co-treatment. The outcome indicators confirmed the worse clinical presentation of GPA, which was associated with a higher rate of hospitalisations (GPA vs. MPA: 25.9 % vs. 8.6 %). Consistently, the analysis of consumption and costs showed in general that patients with GPA and those on glucocorticoid treatment required higher healthcare consumption and costs, mostly for ordinary and day-hospital admissions. Conclusions. AAV is associated with unfavourable outcomes, with GPA more frequent and associated with a worse clinical phenotype. The high utilisation of healthcare resources is mainly due to drug prescriptions and hospitalisations, and partly observed in patients treated with glucocorticoids

Impact and therapy of osteoarthritis: the Arthritis Care OA Nation 2012 survey

Osteoarthritis (OA) is the fastest growing cause of disability worldwide. The aim of this study was to understand the impact of OA on individuals and to explore current treatment strategies. An online UK-wide survey of people with self-reported OA was conducted, composed of 52 questions exploring the impact of OA, diagnosis and treatment, the role of health professionals and self-management. Four thousand forty-three people were invited with 2,001 respondents (49 % response, 56 % women; mean age 65 years). Fifty-two percent reported that OA had a large impact on their lives. Fifteen percent of respondents had taken early retirement on average 7.8 years earlier than planned. In consultations with general practitioners, only half reported a discussion on pain; fewer reported discussing their fears (21 %) or management goals (15 %). Nearly half (48 %) reported not seeking medical help until pain was frequently unbearable. Oral analgesics (62 %), topical therapies (47 %), physiotherapy (38 %) and steroid injections (28 %) were commonly used. The majority (71 %) reported varying degrees of persistent pain despite taking all prescribed medication. Although 64 % knew that increasing exercise was important, only 36 % acted on this knowledge; 87 % who increased exercise found it beneficial. Over half had future concerns related to mobility (60 %), maintaining independence (52 %) and coping with everyday activities (51 %). OA had significant individual economic impact especially on employment. Current treatment strategies still leave most people in pain with significant fears for the future. There is considerable opportunity to improve the holistic nature of OA consultations especially in provision of information and promotion of self-management strategies

Ezetimibe added to statin therapy after acute coronary syndromes

BACKGROUND: Statin therapy reduces low-density lipoprotein (LDL) cholesterol levels and the risk of cardiovascular events, but whether the addition of ezetimibe, a nonstatin drug that reduces intestinal cholesterol absorption, can reduce the rate of cardiovascular events further is not known. METHODS: We conducted a double-blind, randomized trial involving 18,144 patients who had been hospitalized for an acute coronary syndrome within the preceding 10 days and had LDL cholesterol levels of 50 to 100 mg per deciliter (1.3 to 2.6 mmol per liter) if they were receiving lipid-lowering therapy or 50 to 125 mg per deciliter (1.3 to 3.2 mmol per liter) if they were not receiving lipid-lowering therapy. The combination of simvastatin (40 mg) and ezetimibe (10 mg) (simvastatin-ezetimibe) was compared with simvastatin (40 mg) and placebo (simvastatin monotherapy). The primary end point was a composite of cardiovascular death, nonfatal myocardial infarction, unstable angina requiring rehospitalization, coronary revascularization ( 6530 days after randomization), or nonfatal stroke. The median follow-up was 6 years. RESULTS: The median time-weighted average LDL cholesterol level during the study was 53.7 mg per deciliter (1.4 mmol per liter) in the simvastatin-ezetimibe group, as compared with 69.5 mg per deciliter (1.8 mmol per liter) in the simvastatin-monotherapy group (P<0.001). The Kaplan-Meier event rate for the primary end point at 7 years was 32.7% in the simvastatin-ezetimibe group, as compared with 34.7% in the simvastatin-monotherapy group (absolute risk difference, 2.0 percentage points; hazard ratio, 0.936; 95% confidence interval, 0.89 to 0.99; P = 0.016). Rates of pre-specified muscle, gallbladder, and hepatic adverse effects and cancer were similar in the two groups. CONCLUSIONS: When added to statin therapy, ezetimibe resulted in incremental lowering of LDL cholesterol levels and improved cardiovascular outcomes. Moreover, lowering LDL cholesterol to levels below previous targets provided additional benefit